Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab

Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab

Bibliographic Details
Main Authors: Yuri Vladimirovich Muravyev, G I Gridina, D E Karateev
Format: Article
Language:Russian
Published: IMA PRESS LLC 2013-06-01
Series:Научно-практическая ревматология
Online Access:https://rsp.mediar-press.net/rsp/article/view/1663
Description
ISSN:1995-4484
1995-4492

Similar Items